Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Med. Chem. Commun.
2017.0

Abstract

Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by <i>in silico</i> screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

Knowledge Graph

Similar Paper

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells
Med. Chem. Commun. 2017.0
Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing
European Journal of Medicinal Chemistry 2018.0
A New Target for an Old Drug: Identifying Mitoxantrone as a Nanomolar Inhibitor of PIM1 Kinase via Kinome-Wide Selectivity Modeling
Journal of Medicinal Chemistry 2013.0
Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway
Cancer Letters 2022.0
Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor
Bioorganic &amp; Medicinal Chemistry Letters 2009.0
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer
Journal of Medicinal Chemistry 2018.0
Identification of novel ROS inducer by merging the fragments of piperlongumine and dicoumarol
Bioorganic &amp; Medicinal Chemistry Letters 2017.0
Discovery of a new class of MTH1 inhibitor by X-ray crystallographic screening
European Journal of Medicinal Chemistry 2019.0
The Antileukemic and Anti-Prostatic Effect of Aeroplysinin-1 Is Mediated through ROS-Induced Apoptosis via NOX Activation and Inhibition of HIF-1a Activity
Life 2022.0
Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer
ACS Medicinal Chemistry Letters 2013.0